Signal from the log
Matchpoint Therapeutics
150 M$ · Series B · United States
Matchpoint Therapeutics conçoit des petites molécules covalentes, prises par la bouche, contre des cibles de l'auto-immunité jugées difficiles à atteindre. Son premier produit, MPT-062, modulerait l'activation excessive des lymphocytes T et doit entrer en essai chez l'humain en 2027. Levée menée par Nextech Invest et Norwest.
Verified
Announced on , logged by the watch of 7 October 2026.
- Operation
- Funding round
- Announced amount
- 150 M$
- Stage
- Series B
- Country
- United States
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Nextech Invest , Norwest , with Invus , BB Biotech , T1D Fund , BOLD Longevity Growth
Provenance
Source endpoints,globenewswire
Logged on 7 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.